AGENAgenus Inc.
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions The latest analyst update on Agenus centers on a reset of its fair value estimate, with the price target moving from US$30.00 to US$19.50. This change reflects recent Street research that balances optimism about the refocused botensilimab and balstilimab pipeline with caution around financing plans and execution risks. As you read on, you will see how these shifting targets fit into the broader Agenus story and what to watch to keep up with the evolving narrative. Stay updated as the Fair... | ||
 Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates Agenus (AGEN) delivered earnings and revenue surprises of -120.00% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Agenus (AGEN) Earnings Expected to Grow: Should You Buy? Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 Do Options Traders Know Something About Agenus Stock We Don't? Investors need to pay close attention to AGEN stock based on the movements in the options market lately. | ||
 Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing Agenus (AGEN) is back in focus after reporting three year Phase 1b data for its BOT+BAL immunotherapy in refractory microsatellite stable metastatic colorectal cancer, alongside an oversubscribed private placement tied to its registrational ROBBIN trial. See our latest analysis for Agenus. The BOT+BAL data and oversubscribed financing come after a sharp shift in sentiment toward Agenus, with a 7 day share price return of 54.32% and a 30 day share price return of 67.79%, even as the 1 year... | ||
 AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised. | ||
 Agenus stock doubles as biotech narrows Phase 3 bet Agenus is redirecting its Phase 3 colon-cancer strategy. The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of BOT+BAL before colon-cancer surgery, its central development priority. The shift is backed by ... | ||
 Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. | ||
Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed? Earlier this month, Agenus released three-year landmark Phase 1b data showing that its botensilimab plus balstilimab combination produced clinically meaningful long-term survival and durable responses in heavily pretreated patients with refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. An especially interesting finding was the plateau in the Kaplan-Meier survival curve beyond two years and the proportion of patients alive and off systemic... | ||
 AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment Agenus expects to receive about $85 million soon under a placement, with the potential for another $255 million later. | ||
 Agenus shares surge as company secures up to $340M to advance colon cancer trial Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS)... | ||
 Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk stage 2 and stage 3 microsatellite stable colon cancer. Founder, Chairman and Chief Executive Off | ||
 Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) Private Placement Strengthens Funding PositionAgenus Inc. (NASDAQ:AGEN) shares climbed 13% in premarket trading on Monday after the biotechnology company announced an $85 million private placement designed to strengthen its balance sheet and support the continued development of its clinical pipeline. | ||
 Wall Street closes lower as chip selloff and oil surge weigh on markets Investors will balance renewed geopolitical tensions against a busy week for inflation data and the start of bank earnings season | ||
 Agenus surges on study pivot; Apnimed lines up an IPO Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date. | ||
Agenus rises premarket; Micron, Western Digital slide Investing.com - U.S. stock futures were mixed on Monday as investors monitored a sharp selloff across the global memory-chip sector and assessed developments in the biotechnology space. | ||